Delta4 AG is a TechBio company that applies AI, systems biology and computational modeling to discover new indications for drugs with established safety profiles. The company operates the Hyper‑C platform and provides in‑silico models, indication‑expansion services and partnering for drug development.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
AI-powered drug discovery for pharma and biotech companies: target identification, drug repositioning, biomarker identification, side-effect prediction, and clinical trial design.
AI Drug Discovery Platform (Hyper-C)
Hyper-C platform for disease modelling, mechanism-of-action analysis, target prioritization, discovery of new treatment opportunities, and biomarker identification using AI and machine learning.
Drug Development Partnerships
Collaborations with pharma, biotech, academic and clinical partners: computational modelling, disease pathobiology, mechanism-of-action analysis, asset prioritization, biomarker and hypothesis generation, and consortium work.
Preclinical and Clinical Development Programs
Development programs for kidney diseases, oncology, PBC/PSC, and other disease areas, supported by Hyper-C and data-driven prioritization.
Knowledge
No knowledge articles yet
Once Delta4 AG has claimed this profile, we'll publish editorial articles and case studies here together.